DIA announces the appointment of Dr. Holger Adelmann as Senior Vice President & Managing Director for DIA Europe, Middle East and Africa (EMEA), effective Monday, February 15th.  Dr. Adelmann’s appointment signals the next horizon for DIA in the EMEA region as it continues to build from a substantial foundation and to focus on the organization’s vision as the essential partner in catalyzing knowledge creation and sharing to accelerate health care product development.

Previously, Dr Adelmann, MD, PhD, served as the Global Head of Merck Serono’s Clinical Pharmacology and Clinical Biomarker operations, where he re-engineered the Clinical Biomarker and Companion Diagnostics business to align with the upcoming portfolio needs.

Dr. Adelmann holds a board certification in Clinical Pharmacology from the North Rhine medical council, Germany. After clinical training in internal medicine, he joined the pharmaceutical industry in 1989 where he worked in various leading positions with Bayer (Germany), Tropon (Germany), AstraZeneca (UK and Sweden), and Merck Serono (Germany).  He has extensive early and late stage clinical development experience, lead international teams, and was instrumental in various drug submissions. As a core member of a portfolio team, he was involved in several due diligence and M&A activities and leading key strategic disease epidemiology and market access initiatives in Asia. During his time in Sweden, Dr. Adelmann was instrumental in delivering a global inhalation strategy for AstraZeneca. He transformed a former Bayer Clinical Pharmacology unit into an independent CRO business.

Dr. Adelmann is a member of the American Association of Clinical Pharmacology & Therapeutics, a member of the German Association for Applied Human Pharmacology, a fellow of the Royal Microscopical Society, Oxford, and head lecturer for Clinical Pharmacology at the University of Essen-Duisburg, Germany.  After his thesis on the implementation of organizational knowledge management was recognized with an AstraZeneca Global Innovation Award, Dr. Adelmann received a PhD in Information & Knowledge Management from Loughborough University, UK, in 2008.

“DIA’s work across the globe is instrumental in advancing thought leadership through our multi-stakeholder, inter-disciplinary exchange, and our portfolio of programs and products are essential to improving the health care product ecosystem globally,” said Barbara Lopez Kunz, DIA’s Global Chief Executive.  “Holger’s diverse background provides us with the leadership necessary to deliver that trusted, future-oriented knowledge and connect the global health care community to this rapidly evolving region.”  

Dr. Adelmann succeeds Dr. Jytte Lyngvig in this role.